U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564310) titled 'INFORMing Patients With Oximetry Data to Improve MAD Engagement' on April 26.
Brief Summary: Obstructive sleep apnea (OSA) is common and associated with impaired daytime functioning, reduced quality of life and increased cardiovascular, metabolic and perioperative risk.
Mandibular advancement devices (MADs) are a guideline-supported, non-invasive alternative to CPAP for patients with mild to moderate OSA and for those with severe OSA who refuse or cannot tolerate CPAP.
MAD therapy relies heavily on patient engagement and sustained use over time. However, in usual care, patients typically have limited access to objective information ...